There are currently threeFDA-approved semaglutideproducts: As the world's first and currently onlyweekly glucagon-like peptid-1 receptor agonist (GLP-1RA) formulation forlong-term weight management, Semaglutideweight loss achieves an average weight loss of 17% (16.8kg) and providespatients with multiple health benefits beyond weight loss
However, that doesnt mean you cant participate in lower-impact cardiovascular exercise to get that number of minutes up
Wegovy is available in pre-filled, single-dose pens with dosages of 0.25 mg, 0.5 mg, 1.7 mg, or 2.4 mg, while Ozempic is dispensed in pens with adjustable dosing for flexible management
Together, they enhance physical wellness, recovery, and metabolic health, offering potential applications in sports medicine, anti-aging, and personalized healthcare.
References Parasar P, Ozcan P, Terry KL
The units on your syringe are volume measurements, not dose measurements